The purpose of this study is to collect a cohort of patients treated with GLP-1R Agonists and to assess phenotypic, genetic and genomic biomarkers of glycaemic response to these agents.

To develop a cohort of patients treated with GLP-1 R Agonists who are phenotyped at baseline and at 6 month follow up to determine clinical, imaging and other biomarker predictors of glycaemic response to GLP-1R Agonists. The hypothesis is that one, or a combination, of these biomarkers is associated with glycaemic response to GLP-1R Agonists. The primary outcome is therefore HbA1c reduction after 6 months of GLP-1R A treatment.

This is a cohort study of 800 patients being treated with either exenatide or liraglutide for 6 months, and carried out in 4 UK centres.

Inclusion Criteria:

• Patients with Type 2 diabetes where a clinical decision has been made to commence a GLP-1R agonist

• Either:

  1. On any combination of oral hypoglycaemic agents
  2. On Insulin (+/- oral hypoglycaemic agents)

• HbA1c ≥7.5% (58mmol/mol) and HbA1c < 12% (108mmol/mol)

• White European

• Age ≥ 18 and < 80

Exclusion Criteria:

• Type 1 diabetes
• HbA1c <7.5% (58 mmol/mol)
• HbA1c ≥ 12% (108 mmol/mol)
• Pregnancy or lactation
• Any other significant medical reason for exclusion as determined by the investigator
• Inability to consent
• Participating in a CTIMP during the study period and within 30 days prior to study start.